| Title | Therapeutic potential of an AcHERV-HPV L1 DNA vaccine |
|---|---|
| Author | Hee-Jung Lee1, Jong Kwang Yoon1, Yoonki Heo1, Hansam Cho1, Yeondong Cho1, Yongdae Gwon1, Kang Chang Kim1, Jiwon Choi1, Jae Sung Lee2, Yu-Kyoung Oh3, and Young Bong Kim1* |
| Address | 1Department of Bio-industrial Technologies, Konkuk University, Seoul 143-701, Republic of Korea, 2Kolon Life Science, Gyeonggi-do 427-709, Republic of Korea, 3College of Pharmacy, Seoul National University, Seoul 151-742, Republic of Korea |
| Bibliography | Journal of Microbiology, 53(6),415-420, 2015, |
| DOI | 10.1007/s12275-015-5150-0 |
| Key Words | human papillomavirus, vaccine, immunity, cytotoxic T-lymphocytes, anti-tumor |
| Abstract | Cervical cancer is strongly associated with chronic human papillomavirus infections, among which HPV16 is the most common. Two commercial HPV vaccines, Gardasil and Cervarix are effective for preventing HPV infection, but cannot be used to treat existing HPV infections. Previously, we developed a human endogenous retrovirus (HERV)-enveloped recombinant baculovirus capable of delivering the L1 genes of HPV types 16, 18, and 58 (AcHERV-HP16/18/58L1, AcHERV-HPV). Intramuscular administration of AcHERVHPV vaccines induced a strong cellular immune response as well as a humoral immune response. In this study, to examine the therapeutic effect of AcHERV-HPV in a mouse model, we established an HPV16 L1 expressing tumor cell line. Compared to Cervarix, immunization with AcHERVHPV greatly enhanced HPV16 L1-specific cytotoxic T lymphocytes (CTL) in C57BL/6 mice. Although vaccination could not remove preexisting tumors, strong CTL activity retarded the growth of inoculated tumor cells. These results indicate that AcHERV-HPV could serve as a potential therapeutic DNA vaccine against concurrent infection with HPV 16, 18, and 58. |